IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
IDYA(NASDAQ:IDYA) SOUTH SAN FRANCISCO, Calif., Sept. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCLC) in the ongoing Phase 1/2 combination trial of...
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
IDYA(NASDAQ:IDYA) Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US Darovasertib is a small molecule developed for patients with uveal melanoma, a rare type of eye cancer with high unmet medical need IDEAYA will...
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDYA(NASDAQ:IDYA) SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract with data from the company's single-arm, Phase 1/2 trial of darovasertib in combination with crizotinib in...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA(NASDAQ:IDYA) SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 28, 2025, the Compensation Committee of IDEAYA's...
IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025
IDYASOUTH SAN FRANCISCO, Calif., Aug. 18, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its in-person R&D Day in conjunction with the...
IDEAYA Grants Options To Purchase 664,600 Shares To Nine New Hires Under 2023 Inducement Plan
IDYAJP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $66
IDYAIDEAYA Biosciences Q1 EPS $(0.82) Misses $(0.67) Estimate
IDYAIDEAYA Biosciences Receives US FDA IND-Clearance For The Initiation Of A Phase 1 Clinical Trial in Solid Tumors
IDYAThe FDA Clears Ideaya Biosciences' Investigational New Drug Application To Initiate A Phase 1 Trial To Evaluate IDE849 (SHR-4849), A Potential First-in-class Delta-like Ligand 3-targeting Topo-i-payload Antibody Drug Conjugate Program, In Solid Tumors
IDYAIdeaya Biosciences Announced A Successful FDA Type D Meeting On The Phase 3 Registrational Trial For Darovasertib For Potential Regulatory Approval As Neoadjuvant Therapy For Primary Uveal Melanoma, The Phase 3 Randomized Trial Is Expected To Start In 1H
IDYAIdeaya Biosciences Initiated Phase 1/2 Expansion In The Clinical Trial Evaluating IDE397 In Combination With Gilead's Trodelvy In Methylthioadenosine Phosphorylase-deletion Urothelial Cancer Based On Preliminary Safety And Clinical Efficacy Data
IDYAIDEAYA Biosciences Says FDA Granted Breakthrough Therapy Designation For Darovasertib Monotherapy In Neoadjuvant Uveal Melanoma
IDYAIdeaya Biosciences Announced A Research Collaboration With ATTMOS As Part Of Its Efforts To Build A Physics-based Computational Small Molecule Discovery Platform To Target Undruggable Oncology Targets
IDYAStephens & Co. Reiterates Overweight on IDEAYA Biosciences, Maintains $50 Price Target
IDYAIDEAYA Biosciences Expects ~$1.1B Of Cash & Equivalents As Of December 31, 2024, To Fund Operations Into At Least 2028
IDYAIDEAYA Biosciences Q4 2024 GAAP EPS $(1.49) Misses $(0.64) Estimate, Sales $7.00M Beat $4.67M Estimate
IDYARBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $61 Price Target
IDYACantor Fitzgerald Reiterates Overweight on IDEAYA Biosciencesto Overweight
IDYAStephens & Co. Initiates Coverage On IDEAYA Biosciences with Overweight Rating, Announces Price Target of $51
IDYALeerink Partners Downgrades IDEAYA Biosciences to Market Perform, Lowers Price Target to $27
IDYAIDEAYA Biosciences Q3 2024 GAAP EPS $(0.60) Beats $(0.64) Estimate
IDYAWhy Ideaya Biosciences Shares Are Falling Sharply During Wednesday's After-Hours Session
IDYAIdeaya Biosciences Inc (NASDAQ: IDYA) shares are trading lower by 10.07% to $11.25 during Wednesday's after-hours session. The company announced an $80 million common stock offering.
IDEAYA Announces announces $80 million share common stock offering.
IDYAWhere IDEAYA Biosciences Stands With Analysts
IDYAOver the past 3 months, 4 analysts have published their opinion on IDEAYA Biosciences (NASDAQ:IDYA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $32
IDYAIDEAYA Shares Jump On Positive Interim Data From Eye Cancer Trial
IDYAOracle, JPMorgan And 3 Stocks To Watch Heading Into Monday
IDYAWith US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
IDEAYA Announced Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma; Tumor Shrinkage Observed in 31 of 35 Any-Line MUM Patients
IDYALooking Into IDEAYA Biosciences's Return On Capital Employed
IDYABenzinga Pro data, IDEAYA Biosciences (NASDAQ:IDYA) reported Q2 sales of $5.85 million. Earnings fell to a loss of $22.06 million, resulting in a 57.4% decrease from last quarter.
FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma
IDYAThe U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma.
IDEAYA Biosciences Receives Orphan Drug Designation For Darovasertib, A PKC Inhibitor, For The Treatment of Uveal Melanoma
IDYAIDEAYA Biosciences Granted FDA Orphan Drug Designation Wednesday for Darovasertib for Treatment of Uveal Melanoma
IDYA